JP2017502089A - 偏頭痛の処置 - Google Patents

偏頭痛の処置 Download PDF

Info

Publication number
JP2017502089A
JP2017502089A JP2016563885A JP2016563885A JP2017502089A JP 2017502089 A JP2017502089 A JP 2017502089A JP 2016563885 A JP2016563885 A JP 2016563885A JP 2016563885 A JP2016563885 A JP 2016563885A JP 2017502089 A JP2017502089 A JP 2017502089A
Authority
JP
Japan
Prior art keywords
prostaglandin
migraine
analog
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016563885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502089A5 (enExample
Inventor
ブラッツラー，ロバート，エル．
ワンド，マーティン
リックマン，フレデリック
シングルトン，ブラッドフォード，ジェイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Manistee Partners LLC
Original Assignee
Manistee Partners LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manistee Partners LLC filed Critical Manistee Partners LLC
Publication of JP2017502089A publication Critical patent/JP2017502089A/ja
Publication of JP2017502089A5 publication Critical patent/JP2017502089A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016563885A 2014-01-10 2015-01-09 偏頭痛の処置 Pending JP2017502089A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461925676P 2014-01-10 2014-01-10
US61/925,676 2014-01-10
PCT/US2015/010771 WO2015106068A1 (en) 2014-01-10 2015-01-09 Treatment of migraines

Publications (2)

Publication Number Publication Date
JP2017502089A true JP2017502089A (ja) 2017-01-19
JP2017502089A5 JP2017502089A5 (enExample) 2018-02-22

Family

ID=53524356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016563885A Pending JP2017502089A (ja) 2014-01-10 2015-01-09 偏頭痛の処置

Country Status (5)

Country Link
US (2) US9913849B2 (enExample)
EP (1) EP3091985B1 (enExample)
JP (1) JP2017502089A (enExample)
CA (1) CA2935957C (enExample)
WO (1) WO2015106068A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502089A (ja) * 2014-01-10 2017-01-19 マニスティー パートナーズ エルエルシーＭａｎｉｓｔｅｅ Ｐａｒｔｎｅｒｓ Ｌｌｃ 偏頭痛の処置
CN115500876A (zh) * 2019-12-27 2022-12-23 四川大学华西医院 治疗卵圆孔未闭的装置在制备治疗癫痫和/或偏头痛的装置中的用途
WO2022081297A1 (en) * 2020-10-12 2022-04-21 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for lowering intracranial pressure by intranasal agent administration

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510537A (ja) * 2004-08-21 2008-04-10 テーエルテー・メディカル・リミテッド 爪への適用を介した薬物送達
JP2009529057A (ja) * 2006-03-08 2009-08-13 コートリア・コーポレーシヨン Ｃｏｘ−関連胃損傷を予防するための非−選択的ｃｏｘ阻害剤との組み合わせ療法
WO2009103150A1 (en) * 2008-02-20 2009-08-27 Kevin David Smith Method for treating migraine headaches
WO2009151828A1 (en) * 2008-06-12 2009-12-17 Shaw Mari M Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss
JP2014513073A (ja) * 2011-04-05 2014-05-29 オプトソルヴ リミテッド ライアビリティー パートナーシップ 眼科治療

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767619A (en) 1981-09-14 1988-08-30 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Burn wound dressing material
US4511563A (en) 1983-07-15 1985-04-16 Basf Wyandotte Corporation Clear analgesic gels with reduced tackiness
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE3720147A1 (de) 1987-06-16 1988-12-29 Hoechst Ag Antimykotisch wirksamer nagellack sowie verfahren zu dessen herstellung
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US4883660A (en) 1988-10-17 1989-11-28 Thames Pharmacal Co., Inc. Gel bases for pharmaceutical compositions
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
DE4212105A1 (de) 1992-04-10 1993-10-14 Roehm Pharma Gmbh Nagellack zur Behandlung von Onychomykosen
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6011062A (en) 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6224887B1 (en) 1998-02-09 2001-05-01 Macrochem Corporation Antifungal nail lacquer and method using same
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
US7166730B2 (en) 2000-01-27 2007-01-23 Fine Tech Laboratories, Ltd Process for the preparation of prostaglandin derivatives
IL143477A (en) 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
IL134241A (en) 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
AU2001233286B2 (en) 2000-02-01 2006-04-06 Cayman Chemical Company, Incorporated Internal 1,15-lactones of fluprostenol and related prostaglandin F2alpha analogs and their use in the treatment of glaucoma and intraocular hypertension
US6495124B1 (en) 2000-02-14 2002-12-17 Macrochem Corporation Antifungal nail lacquer and method using same
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
KR100581647B1 (ko) 2001-07-17 2006-05-22 파마시아 앤드 업존 캄파니 엘엘씨 라타노프로스트 제조를 위한 방법 및 중간체
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
WO2003079997A2 (en) 2002-03-21 2003-10-02 Cayman Chemical Company Prostaglandin f2 alpha analogs in combinaiotn with antimicrobials for treating glaucoma
US20030049307A1 (en) 2002-08-15 2003-03-13 Gyurik Robert J. Pharmaceutical composition
US7109371B2 (en) 2004-01-05 2006-09-19 Johnson Matthey Public Limited Company Prostaglandin synthesis
KR100850133B1 (ko) 2004-01-05 2008-08-04 니콕스 에스. 에이. 프로스타글란딘 나이트로옥시 유도체
US7666912B2 (en) * 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
IL177762A0 (en) 2006-08-29 2006-12-31 Arieh Gutman Bimatoprost crystalline form i
FR2920309B1 (fr) 2007-08-28 2010-05-28 Galderma Res & Dev Utilisation de travoprost pour traiter la chute des cheveux
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2143712A1 (en) 2008-07-10 2010-01-13 Sandoz AG Improved Process for the Production of Prostaglandins and Prostaglandin Analogs
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
CA2749141A1 (en) 2009-01-08 2010-07-15 Allergan, Inc. Cyclosporine compositions for enhancing nail growth
IT1393112B1 (it) 2009-02-27 2012-04-11 Sifavitor S R L Procedimento per la preparazione di derivati di prostaglandine
WO2011050638A1 (zh) 2009-11-02 2011-05-05 上海天伟生物制药有限公司 一种比马前列素晶体及其制备方法和用途
RU2014117580A (ru) * 2011-10-05 2015-11-10 Аллерган, Инк. Составы для улучшения здоровья ногтей
JP2017502089A (ja) * 2014-01-10 2017-01-19 マニスティー パートナーズ エルエルシーＭａｎｉｓｔｅｅ Ｐａｒｔｎｅｒｓ Ｌｌｃ 偏頭痛の処置

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510537A (ja) * 2004-08-21 2008-04-10 テーエルテー・メディカル・リミテッド 爪への適用を介した薬物送達
JP2009529057A (ja) * 2006-03-08 2009-08-13 コートリア・コーポレーシヨン Ｃｏｘ−関連胃損傷を予防するための非−選択的ｃｏｘ阻害剤との組み合わせ療法
WO2009103150A1 (en) * 2008-02-20 2009-08-27 Kevin David Smith Method for treating migraine headaches
WO2009151828A1 (en) * 2008-06-12 2009-12-17 Shaw Mari M Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss
JP2014513073A (ja) * 2011-04-05 2014-05-29 オプトソルヴ リミテッド ライアビリティー パートナーシップ 眼科治療

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KARAGIANNIS,D.A.ET AL.: "Cessation of migraines in a woman with low-tension glaucoma following the use of latanoprost: a favo", EYE (LONDON, ENGLAND), vol. 21 (2), JPN6018036584, 2007, pages 293 - 295, ISSN: 0004174137 *

Also Published As

Publication number Publication date
US20160324870A1 (en) 2016-11-10
EP3091985A4 (en) 2017-11-29
US20190022105A9 (en) 2019-01-24
US9913849B2 (en) 2018-03-13
WO2015106068A1 (en) 2015-07-16
US20180193354A1 (en) 2018-07-12
US10363258B2 (en) 2019-07-30
EP3091985B1 (en) 2024-05-08
EP3091985A1 (en) 2016-11-16
CA2935957A1 (en) 2015-07-16
CA2935957C (en) 2023-01-03

Similar Documents

Publication Publication Date Title
Lee et al. Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension
EP2552449B1 (en) Compositions comprising brimonidine for the treatment of erythema
JP2009137971A (ja) 薬剤および薬剤キット
JP6924429B2 (ja) 眼科用薬物の定量的な眼窩周囲への適用
US20110275711A1 (en) Method for treating macular edema
JP2025000691A (ja) 脱毛の治療のための組成物
US10363258B2 (en) Treatment of migraines
STEWART et al. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical β-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension
CN106999452B (zh) 前列腺素类和一氧化氮供体的组合产品
Friström A 6‐month, randomized, double‐masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension
JP2014512335A (ja) 毛髪成長を増強するための化合物および方法
CN100496500C (zh) 含布那唑嗪和前列腺素的青光眼治疗剂
JP2007008831A (ja) 口内炎治療のための口腔用組成物
Sorbera et al. Bimatoprost
ES2583127T3 (es) Aplicación transdérmica de prostaglandina E1 para el tratamiento de la isquemia ocular
CN114025768B (zh) 促进毛发生长的药品
JP2003292442A (ja) ブナゾシンとプロスタグランジン類からなる緑内障治療剤
CA3193642A1 (en) Compositions and methods for the treatment of hair loss and other conditions
WO2023141631A3 (en) Formulations and active pharmaceutical ingredients for treating ophthalmic and systemic diseases
Thygesen Travoprost (Travatan®): RAVOPROST RAVATAN John Thygesen
JPWO2005058878A1 (ja) 月経困難症の予防および／または治療剤
Tsukahara et al. Pharmacological mechanisms, clinical effectiveness, and side-effects of prostaglandin analogues as anti-glaucoma agents
HK1241269B (zh) 前列腺素类和一氧化氮供体的组合产品
HK1180208A (en) Compositions comprising brimonidine for the treatment of erythema
HK1180208B (en) Compositions comprising brimonidine for the treatment of erythema

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180109

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191213